Dalia Elganainy

6PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

|Dec 02, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity.

Hannah L Williams, Andressa Dias Costa, Jinming Zhang

|Sep 21, 2022
Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer.

Andressa Dias Costa, Sara A Väyrynen, Akhil Chawla

|Oct 23, 2021
Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma.

Nikhil T Sebastian, Amy Webb, Kenneth W Merrell

|May 20, 2020
Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy.

Joseph D Butner, Dalia Elganainy, Charles X Wang

|Aug 29, 2018
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma.

Dalia Elganainy, Emma B Holliday, Cullen M Taniguchi

Pageof 1

Frequent Collaborators

3 joint publications

Jonathan A Nowak

3 joint publications

Kimberly Perez

3 joint publications

Harshabad Singh

3 joint publications

Douglas A Rubinson